Core Insights - Artelo Biosciences, Inc. has appointed Mark Spring as Chief Financial Officer effective November 1, 2025, enhancing the company's financial leadership as it progresses its clinical pipeline and corporate growth initiatives [1][3] Company Overview - Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company focused on developing treatments that modulate lipid-signaling pathways for various conditions including cancer, pain, and dermatological issues [4] - The company is advancing a portfolio of product candidates aimed at addressing significant unmet medical needs across multiple diseases [4] Leadership Experience - Mark Spring brings 30 years of experience in life sciences, having held financial leadership roles in both private and public companies, including significant experience in mergers and acquisitions [2][3] - His previous roles include interim CFO for LENZ Therapeutics and co-founder and CFO of Secura Bio, among others [2] Strategic Impact - Since joining as a financial consultant in December 2024, Mark Spring has strengthened Artelo's financial operations and supported the execution of its capital strategy [3] - His leadership is expected to be crucial in advancing the company's product candidates and enhancing shareholder value [3]

Core Insights - Artelo Biosciences, Inc. has successfully closed a public offering of 441,210 shares of common stock at a price of $4.40 per share, along with pre-funded warrants for an additional 13,335 shares at $4.399 each, generating approximately $2.0 million in gross proceeds before expenses [1][2]. Offering Details - The offering included a 45-day option for underwriters to purchase up to an additional 68,181 shares to cover over-allotments [2]. - The shares and warrants were offered under a "shelf" registration statement filed with the SEC, which became effective on July 14, 2023 [3]. - The final prospectus supplement and accompanying base prospectus were filed with the SEC on October 1, 2025 [4]. Company Overview - Artelo Biosciences is a clinical-stage pharmaceutical company focused on developing treatments that modulate lipid-signaling pathways for various conditions, including cancer, pain, and dermatologic issues [7]. - The company aims to address significant unmet medical needs through a diversified pipeline and is led by an experienced executive team [7].

Core Viewpoint - Artelo Biosciences, Inc. has successfully closed a public offering of common stock and pre-funded warrants, raising approximately $3.0 million to support its clinical-stage pharmaceutical initiatives focused on lipid-signaling pathways for various medical conditions [1][2]. Group 1: Offering Details - The company offered 640,924 shares of common stock at a public price of $4.40 per share and pre-funded warrants to purchase up to 40,894 shares at a price of $4.399 per warrant [1]. - The gross proceeds from the offering were approximately $3.0 million before deducting underwriting discounts and other expenses [2]. - Underwriters were granted a 45-day option to purchase an additional 102,272 shares at the public offering price to cover over-allotments [2]. Group 2: Regulatory and Documentation - The shares and warrants were offered under a "shelf" registration statement on Form S-3, which was filed with the SEC on July 6, 2023, and declared effective on July 14, 2023 [3]. - The final prospectus supplement and accompanying base prospectus were filed with the SEC on September 5, 2025, and are available on the SEC's website [4]. Group 3: Company Overview - Artelo Biosciences is a clinical-stage pharmaceutical company focused on developing therapeutics that modulate lipid-signaling pathways, addressing significant unmet needs in various medical conditions including cancer and pain [7]. - The company has adopted a corporate finance initiative to deploy excess capital into digital assets as part of its treasury strategy [7].